Traders should monitor how effectively Sonoma Pharmaceuticals deploys the $4.48 million in net proceeds for working capital and corporate purposes. The company's ability to grow revenue from its hypochlorous acid-based product portfolio across dermatology, wound care, and animal health markets will be critical. Given the small market cap of $4 million, this offering provides essential funding but will result in significant dilution to existing shareholders.
Executive Summary
Sonoma Pharmaceuticals is conducting a $5 million public offering of units, each consisting of one share of common stock (or pre-funded warrants) and one common warrant. The net proceeds of approximately $4.48 million will be used for working capital and general corporate purposes. The company operates in the specialty pharmaceutical sector with hypochlorous acid-based products for dermatology, wound care, eye care, and animal health. This offering provides crucial funding for a company with a market cap of just $4 million.
Key Financial Metrics
Key Facts
- Sonoma Pharmaceuticals is offering up to $5 million in units, each consisting of one share of common stock (or pre-funded warrants) and one common warrant
- The offering is priced at $2.47 per unit, based on the closing price on March 18, 2026
- Net proceeds are estimated at $4.48 million after underwriting discounts and expenses
- Proceeds will be used for working capital and general corporate purposes
- The company has 22 FDA clearances and sells products in over 55 countries
- Company has a pharmaceutical-grade manufacturing facility in Guadalajara, Mexico
- Products focus on dermatological conditions, wound care, eye care, podiatry, and animal health
Financial Impact
Approximately $4.48 million in net proceeds from a $5 million offering
Risk Factors
- The offering will result in substantial dilution to new investors of $0.36 per share
- There is no established public trading market for the warrants or pre-funded warrants, limiting liquidity
- The company may not be able to effectively deploy the proceeds to generate growth
- The stock is vulnerable to delisting if it fails to maintain Nasdaq's minimum market value requirements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001683168-26-003052 |
| Document: sonoma_ex0101.htm | 0001683168-26-003052 |
| Document: sonoma_ex0405.htm | 0001683168-26-003052 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.22 $1.16 | ▼ −4.92% | ▼ −4.49% | $1.11 (−9.02%) |
Jun 18, 2026 18w ago | 8-K | $1.16 $1.14 | ▲ +1.72% | ▲ +0.27% | $1.11 (+4.31%) |
Jun 18, 2026 18w ago | 424B5 | $1.16 $1.14 | ▲ +1.72% | ▲ +0.27% | $1.11 (+4.31%) |
Apr 27, 2026 26w ago | 424B4 | $1.11 $1.04 | ▲ +6.31% | ▲ +5.82% | $1.11 (−0.00%) |
Apr 17, 2026 27w ago | S-1 | $2.65 $2.25 | ▼ −15.09% | ▼ −14.44% | $1.11 (−58.11%) |
Apr 9, 2026 28w ago | 8-K | $2.41 $2.28 | ▼ −5.39% | ▼ −5.33% | $1.11 (−53.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers